Kamada Ltd. (NASDAQ:KMDA – Get Free Report) passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $8.00 and traded as high as $8.14. Kamada shares last traded at $8.10, with a volume of 206,789 shares trading hands.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on the company. Stifel Nicolaus set a $12.00 price objective on Kamada in a report on Monday. Wall Street Zen upgraded Kamada from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 15th. Weiss Ratings downgraded Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research report on Monday. Benchmark reiterated a “buy” rating on shares of Kamada in a research note on Tuesday, July 21st. Finally, UBS Group reiterated a “buy” rating and set a $15.00 price target on shares of Kamada in a research note on Friday, September 18th. Four equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, Kamada has a consensus rating of “Buy” and an average price target of $13.75.
Check Out Our Latest Research Report on Kamada
Kamada Stock Performance
The company has a market cap of $467.52 million, a PE ratio of 18.91, a PEG ratio of 0.68 and a beta of 0.90. The company’s 50-day simple moving average is $8.06 and its 200 day simple moving average is $8.00.
Kamada (NASDAQ:KMDA – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The biotechnology company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.01. The business had revenue of $52.03 million for the quarter, compared to analyst estimates of $52.51 million. Kamada had a return on equity of 9.36% and a net margin of 12.67%. Analysts forecast that Kamada Ltd. will post 0.48 EPS for the current year.
Kamada Announces Dividend
The business also recently disclosed a special dividend, which will be paid on Wednesday, December 9th. Stockholders of record on Thursday, November 19th will be paid a $0.14 dividend. The ex-dividend date is Thursday, November 19th. Kamada’s dividend payout ratio (DPR) is presently 97.67%.
Institutional Trading of Kamada
A number of large investors have recently made changes to their positions in KMDA. Aristides Capital LLC raised its holdings in Kamada by 4.5% in the first quarter. Aristides Capital LLC now owns 34,491 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 1,476 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Kamada by 14.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,527 shares of the biotechnology company’s stock worth $92,000 after acquiring an additional 1,346 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Kamada during the 3rd quarter worth approximately $25,000. 20.38% of the stock is currently owned by hedge funds and other institutional investors.
Kamada Company Profile
Kamada Ltd. is an Israeli biopharmaceutical company that develops, manufactures and markets plasma-derived therapies and specialty pharmaceutical products. Founded in 1990, the company is headquartered in Rehovot, Israel. Its products include Glassia, an alpha-1 proteinase inhibitor used to treat people with alpha-1 antitrypsin deficiency, and immune globulin therapies for conditions including rabies exposure, cytomegalovirus infection and varicella-zoster exposure. Kamada serves markets in the United States and internationally, selling products directly and through commercial partners.
See Also
- Five stocks we like better than Kamada
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.
